Background: This study was aimed to study and management of hypertension in diabetic patients.Methods: A prospective, observational study was conducted in 160 diabetic hypertensive patients admitted in general medicine wards at Andhra Pradesh Vaidya Vidhana Parishad Hospital, (APVVP), Proddatur. Patients who signed informed consent form were only included in the study. All the data were recorded from patients’ case files and analyzed.Results: Of enrolled 160 patients, 86 (53.75%) were female and 74 (46.25%) were male and maximum number of the patients 32.5% were found in the age group of 60-69 years. Out of 160 admitted patients, (51) patients treated with metformin, glibenclamide and atenolol, (18) patients treated with metformin, glimiperide, and amlodipine, (6) patients treated with metformin and amlodipine, (28) patients treated with metformin, glimiperide and atenolol, (19) patients treated with metformin and atenolol, (17) patients treated with metformin, glibenclamide and amlodipine,(9) patients treated with metformin, glibenclamide and losartan, (5) patients treated with metformin and losartan, (7) patients treated with metformin, glimiperide, and losartan.Conclusions: There was less awareness among the patients regarding the control of type-2 diabetes mellitus with hypertension. Majority of diabetic patients noticed with hypertension and β adrenergic blockers remained first choice of drug for hypertension in diabetes. Calcium channel blockers were also prescribed to many patients and were successful to achieve target blood pressure. Among anti-diabetic drugs, biguanides were most frequently prescribed class of drugs. Metformin was the most prescribed drug and Sulphonyl urea were the next most prescribed class of drug.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.